Pharmafile Logo

News and Press Releases

Samsung Bioepis Presents Nonclinical Data for its First Novel Antibody-Drug Conjugate Candidate SBE303 at AACR 2026  

Nonclinical findings from pharmacology, pharmacokinetics, and toxicology studies support the advancement of SBE303 into clinical development with a favorable therapeutic index (TI), with its first-in-human Phase I clinical trial began...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 20, 2026

Samsung Bioepis
76, Songdogyoyuk-ro, Yeonsu-gu, Incheon

Integrated DNA Technologies Expands Coralville Manufacturing Footprint to Support Growing Global Demand for MRD Solutions

Expanded footprint delivers speed, scale and customization minimal residual disease (MRD) innovators need without compromising quality Increased production capacity leverages IDT’s highly specialized, high-throughput manufacturing platform. 20 April 2026 --...

Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: April 20, 2026

Integrated DNA Technologies (IDT)
custcare@idtdna.com

Kahimmune Therapeutics signs agreement for scientific collaboration with Gustave Roussy

Agreement will enable selection of Kahimmune’s first companion neoantigen therapy candidate against colorectal cancer and pancreatic cancer, with financial support from Bpifrance   Kahimmune exploits dark genome to develop next-generation...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 18, 2026

Kahimmune Therapeutics
contact@kahimmune.com
2 Avenue Du Blanchissage, 84000 Avignon, France

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026 

Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies and key biomarkers identified AT-108 combines the advantages of an off-the-shelf gene therapy whilst offering a...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 17, 2026

Asgard Therapeutics
info@asgardthx.com
Medicon Village, 223 81 Lund, Sweden

Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure

FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints met Clinically meaningful microbiome modulation observed, including significant improvement up to 6-month follow-up Results...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 16, 2026

Freya Biosciences
info@freyabiosciences.com
Fruebjergvej 3, 2100 Copenhagen, Denmark

STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15

The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications First‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation 16 April...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 16, 2026

Storm Therapeutics
info@stormtherapeutics.com
Babraham Hall House, Babraham, Cambridge CB22 3AT

Oncodesign Services extends collaboration with GIP ARRONAX to strengthen astatine-211 supply for targeted alpha radiotherapy

13 April 2026 -- Dijon, France -- Oncodesign Services has extended its collaboration with GIP ARRONAX to secure access to astatine-211 (At-211) as well as other radionuclides used in targeted...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 13, 2026

Oncodesign Services
contact@oncodesign-services.com
20 Rue Jean Mazen 21 000 Dijon France

Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

First patient dosed in France, expanding the DOMISOL study beyond Australia DT 7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program. 9...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 9, 2026

Kainova Therapeutics
contact@kainovatx.com
7171 Frederick Banting Montreal, QC H4S 1Z9 Canada

ESCMID Global 2026: Shionogi presents new real-world data highlighting clinical effectiveness of Fetroja/Fetcroja (cefiderocol) in MBL-producing Enterobacterales infections

Real world evidence study carried out in Spain demonstrates 68% clinical cure rate at day 14, and 83% overall survival at day 28, for patients infected with highly resistant metallo-beta...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 7, 2026

SHIONOGI
contact@shionogi.eu
33 Kingsway, London, WC2B 6UF, UK

Symeres and Ambagon Therapeutics collaborate on molecular glue research in colorectal cancer

31 March 2026 -- Nijmegen, Netherlands -- Symeres, a leading CRDMO for drug discovery and development has partnered with Ambagon Therapeutics, a pre-clinical biotechnology company, to explore a new class...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 31, 2026

Levicept Announces The Lancet Publication of LEVI-04 Phase II Clinical Trial Results, Showing Significant Reduction in Pain and Symptoms of Osteoarthritis

Significant improvements in pain, function and patient global outcomes demonstrated LEVI-04 well tolerated and exhibits a favourable safety profile. 30 March 2026 -- Sandwich, UK -- Levicept Ltd, a biotechnology...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 30, 2026

Levicept
info@levicept.com
Innovation House Discovery Park Ramsgate Road Sandwich Kent CT13 9ND

Johnson & Johnson’s DARZALEX (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma Milestone is a testament to ten years of daratumumab experience and innovation, continuing...

Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Pharmaceutical
Posted: March 27, 2026

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials 27 March 2026 -- Cambridge, UK -- Positive...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 27, 2026

AstraZeneca
Medical.InformationUK@astrazeneca.com
PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA UK

ADOA PROGRAM – PRESENTATION AT NANOS 2026

PYC is a precision medicine company dedicated to changing the lives of patients with genetic diseases who have no treatment options available One of PYC’s clinical-stage programs is an investigational...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2026

PYC Therapeutics
info@pyctx.com
6 Verdun Street, Nedlands, Western Australia 6009

Tilray Medical Announces Major Expansion of Medical Cannabis Portfolio in Australia

19 March 2026 -- New York, US and Sydney, Australia -- Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc. today announced its...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 19, 2026

Tilray Medical
info@tilraymedical.com